ConductScience.org, home

Paper3720176

Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.

Kleinbloesem CH and 5 others. Clin Pharmacol Ther, 1986. Cited by 105 papers, by iCite.

Cite this record

ConductScience Library. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Papers, record 3720176. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3720176

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
1986
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
105
iCite
Relative citation ratio, by iCite
5.09
iCite
Revised in PubMed
2019-05-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kleinbloesem CHC H
2van Harten JJ
3Wilson JPJ P
4Danhof MM
5van Brummelen PP
6Breimer DDD D

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Blood PressureMajor topic
Liver CirrhosisMajor topic
NifedipineMajor topic
Absorption
Administration, Oral
Adult
Aged
Female
Half-Life
Heart Rate
Humans
Infusions, Parenteral
Kinetics
Male
Middle Aged

Source PubMed

Download CSV of topics

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 105 citations.

PMIDTitleJournalYearIn PapersSource
41499374Using Physiologically Based Pharmacokinetic Modeling and Simulations to Predict Antihypertensive Drug Doses in Cirrhotic Patients.J Clin Pharmacol2026https://conductscience.org/library/papers/41499374PubMed
40614122Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment.Clin Transl Sci2025https://conductscience.org/library/papers/40614122PubMed
34272705Sources of Interindividual Variability.Methods Mol Biol2021https://conductscience.org/library/papers/34272705PubMed
33163829Improving Medication-Related Outcomes in Chronic Liver Disease.Hepatol Commun2020https://conductscience.org/library/papers/33163829PubMed
31112623Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.Br J Clin Pharmacol2019https://conductscience.org/library/papers/31112623PubMed
30052269Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.J Clin Pharmacol2018https://conductscience.org/library/papers/30052269PubMed
27519334Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.Clin Drug Investig1995https://conductscience.org/library/papers/27519334PubMed
27203676Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.Oncotarget2016https://conductscience.org/library/papers/27203676PubMed
27106837Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.AAPS J2016https://conductscience.org/library/papers/27106837PubMed
26070946A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.Clin Pharmacokinet2015https://conductscience.org/library/papers/26070946PubMed
21394568The management of hypertensive emergencies in children after stem cell transplantation.Int J Clin Pharm2011https://conductscience.org/library/papers/21394568PubMed
19212316Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.Clin Pharmacol Ther2009https://conductscience.org/library/papers/19212316PubMed
18762933Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.Eur J Clin Pharmacol2008https://conductscience.org/library/papers/18762933PubMed
16718615CYP induction-mediated drug interactions: in vitro assessment and clinical implications.Pharm Res2006https://conductscience.org/library/papers/16718615PubMed
15924505Dose adjustment in patients with liver disease.Drug Saf2005https://conductscience.org/library/papers/15924505PubMed
12036393Use of sensitivity functions to characterise and compare the forgiveness of drugs.Clin Pharmacokinet2002https://conductscience.org/library/papers/12036393PubMed
11785692Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.Pharm Res2001https://conductscience.org/library/papers/11785692PubMed
10589374Effects of liver disease on pharmacokinetics. An update.Clin Pharmacokinet1999https://conductscience.org/library/papers/10589374PubMed
9820880Effect of hepatic insufficiency on pharmacokinetics and drug dosing.Pharm World Sci1998https://conductscience.org/library/papers/9820880PubMed
9258630Drug administration in chronic liver disease.Drug Saf1997https://conductscience.org/library/papers/9258630PubMed

See all 39 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3720176

GET https://conductscience.org/api/papers/v1/3720176/cited_by?page=2